OncoMatch/Clinical Trials/NCT07493148
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Is NCT07493148 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for diffuse large b-cell lymphoma (dlbcl).
Treatment: Chidamide · Rituximab · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone · Chidamide + Rituximab maintenance — Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (positive)
CD20-positive
Required: MYC overexpression (≥ 40%)
MYC/BCL2 double-expressor: Immunohistochemistry (IHC) per WHO criteria: MYC ≥ 40%, and BCL2 ≥ 50%
Required: BCL2 overexpression (≥ 50%)
MYC/BCL2 double-expressor: Immunohistochemistry (IHC) per WHO criteria: MYC ≥ 40%, and BCL2 ≥ 50%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
Hemoglobin (Hb) ≥ 90 g/L, Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, Platelet count (PLT) ≥ 90 × 10⁹/L
Kidney function
Serum creatinine (Cr) ≤ 1.5 × upper limit of normal (ULN)
Liver function
Total bilirubin (TBIL) ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN in cases of liver metastasis)
Hematology: Hemoglobin (Hb) ≥ 90 g/L, Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, Platelet count (PLT) ≥ 90 × 10⁹/L; Biochemistry: Serum creatinine (Cr) ≤ 1.5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN in cases of liver metastasis)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07493148 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC overexpression is a required biomarker for enrollment.
Does this trial require BCL2?
Yes, BCL2 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify